eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Alliance Pharmaceuticals

Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB
Telephone: +44 (0)1249 466 966
Fax: +44 (0)1249 466 977
WWW: http://www.alliancepharma.co.uk
Medical Information e-mail: medinfo@alliancepharma.co.uk

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 17/11/2011
SPC Lysovir 100mg Capsules

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/11/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 6.1 - List of Excipients
Date of revision of text on the SPC:   11-Nov-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Amendments highlighted below:


Lactose, povidone, magnesium stearate. Capsule shell: gelatin, titanium dioxide (E171),
red iron oxide (E172). And monogramming ink S-1-7085  wWhite printing ink: Opacode S-1-7020 containing, Shellac, I.M.S. 74 OP, purified water, soya lecithin (E322), 2-ethoxyethanol, antifoam DC 1510, titanium dioxide (E171), ammonium hydroxide 28%, propylene glycol (E1520), simethicone or SB-0007P white ink containing: shellac, propylene glycol, sodium hydroxide, povidone, titanium dioxide (E171).

Updated on 19/08/2010 and displayed until 17/11/2011
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic Properties
Date of revision of text on the SPC:   22-Jun-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



4.4 Special warnings and precautions for use

 

Now includes the following red text:

 

Amantadine has anticholinergic effects, it should not be given to patients with untreated angle closure glaucoma.

 

Hypothermia has been observed in children, especially in those younger than 5 years of age. Caution should be exercised when prescribing Lysovir to children for the prevention and treatment of influenza type A virus (see also section 4.2 Posology and method of administration).

 

4.8       Undesirable effects

 

Now includes the following red text:

 

Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (greater than or equal to 1 in 10); common (less than or equal to 1 in 100, less than 1 in 10); uncommon (greater than or equal to 1 in 1,000, less than 1 in 100); rare (greater than or less than 1 in 10,000, less than 1 in 1,000) very rare (less than 1 in 10,000), not known (where no valid estimate of the incidence has been derived).

 

NB: The incidence and severity of some of the adverse reactions, noted below, varies according to the dosage and nature of the disease under treatment.

 

Blood and lymphatic system disorders: 

Very rare:              leucopenia, reversible elevation of liver enzymes. 

 

Nervous system disorders:

Common:              anxiety, elevation of mood, lightheadedness, headache, lethargy, hallucinations, nightmares, ataxia, slurred speech, blurred vision, loss of concentration, nervousness, depression, insomnia, myaligia..  Hallucinations, confusion and nightmares1 

Rare:                     confusion, disorientation, psychosis, tremor, dyskinesia, convulsions, neuroleptic malignant-like syndrome.

Not known:            Delirium, hypomanic state and mania2  

 

Eye Disorders:

Rare:                     corneal lesions, e.g. punctate subepithelial opacities which might be associated with superficial punctate keratitis, corneal epithelial oedema, and markedly reduced visual acuity

 

Cardiac disorders: 

Very common:      oedema of ankles, livedo reticularis3. 

Common:              palpitations, orthostatic hypotension

Very rare:              heart insufficiency/failure

 

Gastrointestinal disorders: 

Common:              dry mouth, anorexia, nausea, vomiting, constipation 

Rare:                     diarrhoea 

 

Skin and subcutaneous disorders:

Common:              diaphoresis

Rare:                     exanthema

Very rare:              photosensitisation. 

 

Renal and urinary disorders:

 Rare:                    urinary retention, urinary incontinence.

 

General disorders

Not known:        Hypothermia4

 

 

1more common when amantadine is administered concurrently with anticholinergic agents or when the patient has an underlying psychiatric disorder.

 

2reported but their incidence cannot be readily deduced from the literature.

 

3usually after very high doses or use over many months.

 

4In post-marketing exposure hypothermia has been reported in children mainly those younger than 5 years of age (see also section 4.4 Special warnings and precautions for use). The frequency can not be established

 

 

 

 

 

4.9              Overdose

 

Now includes the following red text:

 

Overdose with Lysovir can lead to fatal outcome.

 

Signs and symptoms: Neuromuscular disturbances and symptoms of acute psychosis are prominent. Central nervous system: Hyperreflexia, motor restlessness, convulsions, extrapyramidal signs, torsion spasms, dystonic posturing, dilated pupils, dysphagia, confusion, disorientation, delirium, visual hallucinations, myoclonus. Respiratory system: hyperventilation, pulmonary oedema, respiratory distress, including adult respiratory distress syndrome. Cardiovascular system: cardiac arrest and sudden cardiac death have been reported. Sinus tachycardia, arrhythmia, hypertension. Gastrointestinal system: nausea, vomiting, dry mouth. Renal function: urine retention, renal dysfunction, including increase in BUN and decreased creatinine clearance.

 

5.1       Pharmacodynamic properties

 

Now includes the following red text:

 

Pharmacotherapeutic group: Anti-influenzal virostatic

 

ATC code N04B B01

Updated on 10/02/2009 and displayed until 19/08/2010
Reasons for adding or updating:
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6.1 - List of Excipients
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   04-Feb-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



3.             Pharmaceutical form

Reddish-brown hard gelatin capsules, printed SYMM in white on both the cap and body.

 

4.4.    Special warnings and precautions for use

A similar syndrome has also been reported rarely following withdrawal of amantadine and other anti-Parkinson agents in patients who were not taking concurrent psychoactive medication.

 

4.8     Undesirable effects

         neuroleptic malignant-like syndrome

 

6.1     List of excipients

red iron oxide (E172).  White printing ink: Opacode S-1-7020 containing, Shellac, I.M.S. 74 OP, purified water, soya lecithin (E322), 2-ethoxyethanol, antifoam DC 1510, titanium dioxide (E171).

Updated on 10/08/2005 and displayed until 10/02/2009
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
  • Change to section 6.1 - List of Excipients
  • Change to section 10 (date of (partial) revision of the text
Updated on 01/09/2004 and displayed until 10/08/2005
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
  • Change to section 10 (date of (partial) revision of the text
Updated on 16/07/2001 and displayed until 01/09/2004
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 01/03/2000 and displayed until 16/07/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   amantadine hydrochloride